Pharvaris NV Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
30.7%projected annual EPS growth
Analyst Coverage
14analysts covering
FY EPS (est.)
-$3.25next fiscal year
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly247MTarget: Sufficient to fund operations into 2028
R&D Expenses Quarterly29.9MTarget: Disciplined capital allocation prioritizing deucrictibant late-stage trials
Watch Items
- CHAPTER-3 Phase 3 Topline Data ReadoutTrigger: Topline efficacy and safety results of deucrictibant XR for HAE prophylaxisAction: Evaluate clinical profile against existing prophylactic standards (e.g., Takhzyro, Orladeyo)
- NDA Submission for Deucrictibant IRTrigger: Submission of marketing authorization application to the FDA in 1H2026Action: Monitor FDA acceptance of filing and review timeline (standard vs priority)
- CREAATE Phase 3 Trial EnrollmentTrigger: Progress of patient enrollment in the CREAATE study for AAE-C1INHAction: Assess timeline for potential label expansion into acquired angioedema
Research as of 20 Jun 2026